New oral treatment approved for plaque psoriasis
People with psoriasis have a new treatment option.
The U.S. Food and Drug Administration approved Otezla (apremilast) as a 30-milligram tablet taken twice a day for moderate to severe plaque psoriasis.
Otezla, a new type of oral drug, offers another option for people who are candidates for phototherapy and systemic drugs and are not responding to topical treatments.
Otezla was FDA-approved on March 21, 2014 for the treatment of adults with active psoriatic arthritis.
September 23, 2014
About the National Psoriasis Foundation
Serving its community through more than 50 years of patient support, advocacy, research funding, and education, the National Psoriasis Foundation (NPF) is the world’s leading nonprofit fighting for individuals with psoriasis and psoriatic arthritis. The NPF mission is to drive efforts to cure psoriatic disease and dramatically improve the lives of more than 8 million Americans affected by this chronic immune-mediated disease. As part of that effort, NPF created its Patient Navigation Center to offer personalized assistance to everyone with psoriasis or psoriatic arthritis. To date, NPF has funded more than $21 million in research grants and fellowships that help drive discoveries that may lead to more and better treatments and ultimately a cure. Learn more at www.psoriasis.org.